A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose

Yoshimi Tsuda; Christopher J. Parkins; Patrizia Caposio; Friederike Feldmann; Sara Botto; Susan Ball; Ilhem Messaoudi; Luka Cicin-Sain; Heinz Feldmann; Michael A. Jarvis

doi:10.1016/j.vaccine.2015.03.029

A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose

Yoshimi Tsuda
, Christopher J. Parkins
, Patrizia Caposio
, Friederike Feldmann
, Sara Botto
, Susan Ball
, Ilhem Messaoudi
, Luka Cicin-Sain
, Heinz Feldmann
, Michael A. Jarvis

Research output: Contribution to journal › Article › peer-review

54 Scopus citations

Abstract

Ebola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.

Original language	English
Pages (from-to)	2261-2266
Number of pages	6
Journal	Vaccine
Volume	33
Issue number	19
DOIs	https://doi.org/10.1016/j.vaccine.2015.03.029
State	Published - May 1 2015

Bibliographical note

Publisher Copyright:
© 2015 Elsevier Ltd.

Funding

We thank Dr U. Koszinowski (Max von Pettenkofer-Institute, Ludwig-Maximilians-University, Germany) for providing the pSMfr3 MCMV BAC, and Dr D. Court (NCI-Frederick, MD) for providing the lambda-based recombination system used to construct the original MCMV/ZEBOV-NP CTL construct. We appreciate K. Marshall (VGTI, OR) and J. Bailey (NIAID, MT) for their organization and coordination of animals used in the study. We also thank the members of Rocky Mountain Veterinary Branch (DIR, NIAID , NIH) for assistance with animal care. Finally, we thank Drs H. Ebihara (DIR, NIAID , NIH), A. Marzi (DIR, NIAID , NIH), P. Barry (University of California at Davis, CA), M. Cranfield (Mountain Gorilla Veterinary Project, Baltimore, MD) for insightful discussions. This study was supported by R21 (AI088442) and the Intramural Research Program of the NIAID , NIH ; and University of Plymouth, School of Biomedical and Healthcare Sciences internal funding.

Funders	Funder number
National Institutes of Health (NIH)
Plymouth Marjon University
National Institute of Allergy and Infectious F32-AI286447 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI168214 Jason W. Rosch Diseases National Institute of Allergy and Infectious P30 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R00-AI166116 Christopher D. Radka Diseases National Institute of Allergy and Infectious T32-AI106700 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI192221 Jason W. Rosch Diseases National Inst...	ZIAAI001089, R21AI088442

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cytomegalovirus
Disseminating
Durable
Ebola
Ebolavirus
Great apes
Mouse
Protection
Vaccine

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2015.03.029

Cite this

@article{63014c77f1fc4fe3b48d6dec0b38c1d5,

title = "A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose",

abstract = "Ebola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.",

keywords = "Cytomegalovirus, Disseminating, Durable, Ebola, Ebolavirus, Great apes, Mouse, Protection, Vaccine",

author = "Yoshimi Tsuda and Parkins, \{Christopher J.\} and Patrizia Caposio and Friederike Feldmann and Sara Botto and Susan Ball and Ilhem Messaoudi and Luka Cicin-Sain and Heinz Feldmann and Jarvis, \{Michael A.\}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Ltd.",

year = "2015",

month = may,

day = "1",

doi = "10.1016/j.vaccine.2015.03.029",

language = "English",

volume = "33",

pages = "2261--2266",

number = "19",

}

TY - JOUR

T1 - A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose

AU - Tsuda, Yoshimi

AU - Parkins, Christopher J.

AU - Caposio, Patrizia

AU - Feldmann, Friederike

AU - Botto, Sara

AU - Ball, Susan

AU - Messaoudi, Ilhem

AU - Cicin-Sain, Luka

AU - Feldmann, Heinz

AU - Jarvis, Michael A.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Ebola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.

AB - Ebola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.

KW - Cytomegalovirus

KW - Disseminating

KW - Durable

KW - Ebola

KW - Ebolavirus

KW - Great apes

KW - Mouse

KW - Protection

KW - Vaccine

UR - https://www.scopus.com/pages/publications/84929574655

UR - https://www.scopus.com/pages/publications/84929574655#tab=citedBy

U2 - 10.1016/j.vaccine.2015.03.029

DO - 10.1016/j.vaccine.2015.03.029

M3 - Article

C2 - 25820063

AN - SCOPUS:84929574655

SN - 0264-410X

VL - 33

SP - 2261

EP - 2266

JO - Vaccine

JF - Vaccine

IS - 19

ER -

A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this